aTYR PHARMA (ATYR) Depreciation & Amortization (CF) (2014 - 2026)

aTYR PHARMA (ATYR) has reported Depreciation & Amortization (CF) for 13 consecutive years, with $168000.0 the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Depreciation & Amortization (CF) rose 1.2% year-over-year to $168000.0; the trailing twelve-month figure through Jun 2026 stood at $697000.0 (up 1.6% YoY), and the FY2025 full-year result was $700000.0, down 1.13% from the prior year.
• Depreciation & Amortization (CF) climbed to $168000.0 in Q2 2026 per ATYR's latest filing, from $162000.0 in the prior quarter.
• Across five years, Depreciation & Amortization (CF) topped out at $202000.0 in Q4 2025 and bottomed at $39000.0 in Q4 2022.
• Historically, Depreciation & Amortization (CF) has averaged $142777.8 across 5 years, with a median of $166500.0 in 2025.
• The sharpest annual moves came in 2022 and 2023: Depreciation & Amortization (CF) slumped 70.68% in 2022, then jumped 369.23% in 2023.
• Over 5 years, Depreciation & Amortization (CF) stood at $39000.0 in 2022, then surged by 369.23% to $183000.0 in 2023, then decreased by 4.37% to $175000.0 in 2024, then advanced by 15.43% to $202000.0 in 2025, then declined by 16.83% to $168000.0 in 2026.
• According to Business Quant data, Depreciation & Amortization (CF) over the past three periods registered $168000.0, $162000.0, and $202000.0 for Q2 2026, Q1 2026, and Q4 2025 respectively.